Immunochemical detection of flucloxacillin adduct formation in livers of treated rats

Toxicology

Volumn 216, Issue 1, 2005, Pages 41-48

  Carey, Michelle A ^a,b   Van Pelt, Frank N A M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Cholestasis; Drug adduct; ELISA; Flucloxacillin; Immunoblotting

Indexed keywords

FLUCLOXACILLIN; LIVER PROTEIN; OVALBUMIN; POLYCLONAL ANTISERUM; SERUM ALBUMIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CELLULAR DISTRIBUTION; CONJUGATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOCHEMISTRY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; RABBIT; WESTERN BLOTTING;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOXACILLIN; IMMUNE SERA; LIVER; MALE; PROTEINS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SUBCELLULAR FRACTIONS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 27444444430     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2005.07.015     Document Type: Article

References (31)

1. F. Bengtsson, C.H. Floren, I. Hagerstrand, C. Soderstrom, and T. Aberg Flucloxacillin-induced cholestatic liver damage Scand. J. Infect. Dis. 17 1985 125 128
2. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
3. U. Christen, M. Burgin, and J. Gut Halothane metabolism: immunochemical evidence for molecular mimicry of trifluoroacetylated liver protein adducts by constitutive polypeptides Mol. Pharmacol. 40 1991 390 400
4. P.H. Corran, and S.G. Waley The reaction of penicillin with proteins Biochem. J. 149 1975 357 364
5. M.H. Davies, R.F. Harrison, E. Elias, and S.G. Hubscher Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis J. Hepatol. 20 1994 112 116
6. G. Deboever Cholestatic jaundice due to derivatives of oxacillin Am. J. Gastroenterol. 82 1987 483
7. L.E. Derby, H. Jick, D.A. Henry, and A.D. Dean Cholestatic hepatitis associated with flucloxacillin Med. J. Aust. 158 1993 596 600
8. B.M. Devereaux, D.H. Crawford, P. Purcell, L.W. Powell, and H.P. Roeser Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur. J. Clin. Pharmacol. 49 1995 81 85
9. C. Dollery Floxacillin C. Dollery Therapeutic Drugs 1999 Churchill Livingston London F57 F62
10. R.P. Eckstein, J.F. Dowsett, and M.R. Lunzer Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy Pathology 25 1993 223 228
11. C.K. Fairley, I. Boyd, P. Purcell, and J. McNeil Flucloxacillin jaundice Lancet 339 1992 679
12. M.A. Freedman Oxacillin-apparent hematologic and hepatic toxicity Rocky Mt. Med. J. 62 1965 34 36
13. J. Gath, B. Charles, J. Sampson, and B. Smithurst Pharmacokinetics and bioavailability of flucloxacillin in elderly hospitalized patients J. Clin. Pharmacol. 35 1995 31 36
14. P. Gotell, and L. Loof Effects of floxacillin on the liver. Three cases of floxacillin-induced cholestatic liver disease Lakartidningen 84 1987 954 955
15. A.F. Habeeb Determination of free amino groups in proteins by trinitrobenzenesulfonic acid Anal. Biochem. 14 1966 328 336
16. J. Hewitt, and L. Hammond Adverse hepatic events associated with drug therapy Med. J. Aust. 165 347 1996 350
17. J.G. Kenna, J. Neuberger, and R. Williams An enzyme-linked immunosorbent assay for detection of antibodies against halothane-altered hepatocyte antigens J. Immunol. Methods 75 1984 3 14
18. J.G. Kenna, T.L. Knight, and F.N. van Pelt Immunity to halothane metabolite-modified proteins in halothane hepatitis Ann. N. Y. Acad. Sci. 685 1993 646 661
19. N.R. Kitteringham, G. Christie, J.W. Coleman, J.H. Yeung, and B.K. Park Drug-protein conjugates-XII. A study of the disposition, irreversible binding and immunogenicity of penicillin in the rat Biochem. Pharmacol. 36 1987 601 608
20. G.H. Koek, B.H. Stricker, A.P. Blok, S.W. Schalm, and V.J. Desmet Flucloxacillin-associated hepatic injury Liver 14 1994 225 229
21. F. Lakehal, P.M. Dansette, L. Becquemont, E. Lasnier, R. Delelo, P. Balladur, R. Poupon, P.H. Beaune, and C. Housset Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes Chem. Res. Toxicol. 14 2001 694 701
22. S. Lobatto, B.A. Dijkmans, H. Mattie, and J.P. Van Hooff Flucloxacillin-associated liver damage Neth. J. Med. 25 1982 47 48
23. J.J. McNeil, E.A. Grabsch, and M.M. McDonald Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story Med. J. Aust. 170 1999 270 273
24. M. Miros, P. Kerlin, N. Walker, and O. Harris Flucloxacillin induced delayed cholestatic hepatitis Aust. N. Z. J. Med. 20 1990 251 253
25. R. Olsson, B.E. Wiholm, C. Sand, L. Zettergren, R. Hultcrantz, and M. Myrhed Liver damage from flucloxacillin, cloxacillin and dicloxacillin J. Hepatol. 15 1992 154 161
26. A. Piotrowicz, M. Polkey, and M. Wilkinson Ursodeoxycholic acid for the treatment of flucloxacillin-associated cholestasis J. Hepatol. 22 1995 119 120
27. P. Tauris, N.F. Jorgensen, C.M. Petersen, and K. Albertsen Prolonged severe cholestasis induced by oxacillin derivatives. A report on two cases Acta Med. Scand. 217 1985 567 569
28. H.H. Thijssen Identification of the active metabolites of the isoxazolylpenicillins by means of mass-spectrometry J. Antibiot. (Tokyo) 32 1979 1033 1037
29. I.B. Turner, R.P. Eckstein, J.W. Riley, and M.R. Lunzer Prolonged hepatic cholestasis after flucloxacillin therapy Med. J. Aust. 151 1989 701 705
30. T. Vial, M. Biour, J. Descotes, and C. Trepo Antibiotic-associated hepatitis: update from 1990 Ann. Pharmacother. 31 1997 204 220
31. R.M. Victorino, V.A. Maria, A.P. Correia, and C. de Moura Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization Arch. Intern. Med. 147 1987 987 989